DANIEL FERNANDES SARAGIOTTO

(Fonte: Lattes)
Índice h a partir de 2011
3
Lattes
Projetos de Pesquisa
Unidades Organizacionais

Filtros

Limpar filtros

Configurações

Resultados de Busca

Agora exibindo 1 - 10 de 30
  • conferenceObject
    Safety and efficacy of adjuvant modified FLOX for patients (pts) with stage III colorectal cancer (CRC) treated in the community.
    (2015) PROTASIO, Bruno Mendonca; MATUTINO, Adriana Reis Brandao; LAGE, Liana Valente; SANTANA, Iuri Amorim De; RAMOS, Ricardo Emanuel De Oliveira; CAIRES-LIMA, Rafael; CAIRES, Inacelli Queiroz De Souza; RIECHELMANN, Rachel Pimenta; SARAGIOTTO, Daniel Fernandes; SABBAGA, Jorge; HOFF, Paulo Marcelo
  • article 47 Citação(ões) na Scopus
    Pregabalin for the Prevention of Oxaliplatin-Induced Painful Neuropathy: A Randomized, Double-Blind Trial
    (2017) ANDRADE, Daniel Ciampi De; TEIXEIRA, Manoel Jacobsen; GALHARDONI, Ricardo; FERREIRA, Karine S. L.; MILENO, Paula Braz; SCISCI, Nathalia; ZANDONAI, Alexandra; TEIXEIRA, William G. J.; SARAGIOTTO, Daniel F.; SILVA, Valquiria; RAICHER, Irina; CURY, Rubens Gisbert; MACARENCO, Ricardo; HEISE, Carlos Otto; BROTTO, Mario Wilson Iervolino; MELLO, Alberto Andrade De; MEGALE, Marcelo Zini; DOURADO, Luiz Henrique Curti; BAHIA, Luciana Mendes; RODRIGUES, Antonia Lilian; PARRAVANO, Daniella; FUKUSHIMA, Julia Tizue; LEFAUCHEUR, Jean-Pascal; BOUHASSIRA, Didier; SOBROZA, Evandro; RIECHELMANN, Rachel P.; HOFF, Paulo M.; SILVA, Fernanda Valerio Da; CHILE, Thais; DALE, Camila S.; NEBULONI, Daniela; SENNA, Luiz; BRENTANI, Helena; PAGANO, Rosana L.; SOUZA, Angela M. De
    Background. Patients with colorectal cancer (CRC) receiving oxaliplatin (OXA) develop acute and chronic painful oxaliplatin-induced peripheral neuropathy (OXAIPN). Acute and chronic OXA-related neuropathies have different pathophysiological bases, but both lead to a common phenomenon: central sensitization (CS) of nociceptive neuronal networks, leading to increased sensitivity (hyperlgesia, allodynia) in the somatosensory system, the common ground of chronic neuropathic pain. Because CS is related to increased risk of painful OXAIPN, we hypothesized that preemptive use of the anti-hyperalgesic drug pregabaline (known to decrease CS) during OXA infusions would decrease the incidence of chronic OXAIPN. Methods. Pain-free, chemotherapy-naive CRC patients receiving at least one cycle of modified-FLOX [5-FU(500 mg/m(2)) 1 leucovorin(20 mg/m(2))/week for] 6 weeks+oxaliplatin(85 mg/m2) at weeks 1-3-5 every 8 weeks] were randomized (1:1) into the study. Patients received either pregabalin or placebo for 3 days before and 3 days after each OXA infusion and were followed for up to 6 months. Clinical assessments were performed at baseline, at the end of chemotherapy, and after the follow-up period. The main outcome was average pain at the last visit assessed by the visual analogic scale (0-10) item of the Brief Pain Inventory (BPI). Secondary endpoints were presence of neuropathic pain according to the Douleur Neuropathique-4 (DN-4), pain dimensions (short-form McGill Pain Questionnaire [MPQ]), Neuropathic Pain Symptom Inventory (NPSI), and changes in nerve conduction studies (NCS) and side effect profile. Results. One hundred ninety-nine patients (57.0 +/- 10.7 years old, 98 female, 101 male) were randomized. Data from 56 patients were not included in the analyses (as they did not receive at least one full cycle of modified FLOX). Data from 78 patients in the pregabalin group and 65 patients in the placebo group were retained for analyses. At the last visit, pain intensity in the pregabalin group was 1.03 (95% confidence interval [CI] 50.79-1.26), and 0.85 (95% CI50.64-1.06) in the placebo group, which did not reach significance. Scores from the BPI, MPQ, DN-4, NPSI, and NCS and side-effect profiles and incidence of death did not differ between groups. Quality of life (QoL) score did not differ between groups (placebo = 576.9 +/- 23.1, pregabalin group 79.4 +/- 20.6). Mood scores were not significantly different between groups (placebo 9.7 [8.1-11.2]; pregabalin 6.8 [5.6-8.0]). Conclusion. The preemptive use of pregabalin during OXA infusions was safe, but did not decrease the incidence of chronic pain related to OXAIPN.
  • bookPart
    Câncer de Esôfago
    (2014) HOFF, Paulo M. G.; SABBAGA, Jorge; COSTA, Frederico P.; FERNANDES, Gustavo dos Santos; CAPARELI, Fernanda; SARAGIOTTO, Daniel; PEREIRA, Guilherme Stelko; PFIFFER, Tulio; BEZERRA NETO, João Evangelista
  • conferenceObject
    A phase III, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of pregabalin in the prevention and reduction of oxaliplatin-induced painful neuropathy (PreOx)
    (2015) ANDRADE, Daniel Ciampi de; TEIXEIRA, Manoel Jacobsen; GALHARDONI, Ricardo; FERREIRA, Karine A. S. L.; MALIENO, Paula Braz; SCISCI, Nathalia; RIECHELMANN, Rachel Pimenta; TEIXEIRA, William G. J.; SARAGIOTTO, Daniel Fernandes; SILVA, Valquiria Aparecida; RAICHER, Irina; CASTRO, Isac de; PARRAVANO, Daniella; FUKUSHIMA, Julia Tizue; LEFAUCHEUR, Jean-Pascal; BOUHASSIRA, Didier; MACARENCO, Ricardo Silvestre e Silva; MELLO, Evandro Sobroza de; HOFF, Paulo Marcelo
  • bookPart
    Câncer de Canal Anal
    (2014) HOFF, Paulo M. G.; SABBAGA, Jorge; COSTA, Frederico P.; FERNANDES, Gustavo dos Santos; CAPARELI, Fernanda; SARAGIOTTO, Daniel; PEREIRA, Guilherme Stelko; PFIFFER, Tulio; BEZERRA NETO, João Evangelista
  • conferenceObject
    Phase II study of capecitabine in substitution of 5-FU in the chemoradiotherapy regimen for patients with squamous cell carcinoma of the anal canal.
    (2012) RIBEIRO, Suilane Coelho; VENCHIARUTTI, Camila; RIECHELMANN, Rachel; GIL, Erlon; NAHAS, Caio; COUDRY, Renata; FREITAS, Daniela; SARAGIOTTO, Daniel F.; ARRUDA, Fernando; AZAMBUJA, Rodrigo; HOFF, Paulo
  • bookPart
    Neoplasia de sítio primário indeterminado
    (2017) MAK, Milena Perez; TAKAHASHI, Tiago Kenji; SARAGIOTTO, Daniel Fernandes
  • article 37 Citação(ões) na Scopus
    Randomized Phase III Trial Exploring the Use of LongActing Release Octreotide in the Prevention of Chemotherapy-Induced Diarrhea in Patients With Colorectal Cancer: The LARCID Trial
    (2014) HOFF, Paulo M.; SARAGIOTTO, Daniel F.; BARRIOS, Carlos H.; GIGLIO, Auro del; COUTINHO, Anelisa K.; ANDRADE, Aline C.; DUTRA, Carolina; FORONES, Nora M.; CORREA, Mariangela; PORTELLA, Maria do Socorro O.; PASSOS, Vanessa Q.; CHINEN, Renata N.; EYLL, Brigitte van
    Purpose Chemotherapy-induced diarrhea (CID) is a relatively common adverse event in the treatment of patients with colorectal cancer. The LAR for Chemotherapy-Induced Diarrhea (LARCID) trial evaluated the efficacy and safety of long-acting release octreotide (octreotide LAR) for the prevention of CID in this population. Patients and Methods Patients with colorectal cancer starting adjuvant or first-line treatment with a chemotherapy combination containing fluorouracil, capecitabine, and/or irinotecan were randomly assigned to receive octreotide LAR 30 mg intramuscularly every 4 weeks (experimental arm) or the physician's treatment of choice in case of diarrhea (control arm). Results A total of 139 patients were randomly assigned, most of whom received fluorouracil- and oxaliplatin-containing chemotherapy regimens. The rate of diarrhea was 76.1% in the experimental group (n = 68) and 78.9% in the control group (n = 71). Treatment with octreotide LAR did not prevent or reduce the severity of CID. Treatment choices for diarrhea management included loperamide in the majority of patients. No benefit from octreotide LAR was identified in terms of need for diarrhea treatment, opioids, or intravenous hydration or in the rate of hospitalization or quality of life. Conclusion This study could not prove the efficacy of octreotide LAR in the prevention of CID.
  • bookPart
    Prevenção primária e secundária do câncer
    (2016) SARAGIOTTO, Daniel Fernandes
  • bookPart
    Neoplasias de sítio primário indeterminado
    (2015) MAK, Milena Perez; TAKAHASHI, Tiago Kenji; SARAGIOTTO, Daniel Fernandes